Addiction treatment and therapy involves a multifaceted approach, combining various therapeutic methods tailored to tackle different aspects of substance abuse and behavioral dependencies. Cognitive-behavioral therapy (CBT) and dialectical behavior therapy (DBT) are prominent among these, offering a supportive environment for individuals to delve into the root causes of their addictive behaviors. Through these therapies, people not only uncover triggers and cravings but also acquire vital coping strategies and problem-solving skills to effectively manage them. In addition to therapy, addiction treatment includes pharmacological interventions like medication-assisted treatment (MAT) and detoxification services. MAT helps ease withdrawal symptoms and cravings, stabilizing brain chemistry to make the initial recovery stages more manageable and safer. During this crucial phase, detox services offer vital medical assistance, guaranteeing the physical well-being and comfort of individuals navigating withdrawal. Ongoing support is essential for maintaining sobriety and navigating post-treatment challenges. Support groups, peer mentoring programs, and aftercare services create a sense of community and accountability, offering encouragement and guidance during the transition back into society. Family therapy is also crucial, addressing the impact of addiction on familial relationships and fostering healing among loved ones. Ultimately, addiction treatment is a comprehensive approach that integrates therapy, medical support, and holistic methods to address addiction's complex nature. By empowering individuals to explore, heal, and transform themselves, treatment enables them to regain control of their lives, form meaningful connections, and embrace a future free from addiction.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States